Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
- PMID: 28248853
- PMCID: PMC5340426
- DOI: 10.1097/MD.0000000000005904
Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
Abstract
Hepatocellular carcinoma (HCC) is among the most common types of cancer. Liver transplantation (LT) and surgical resection (SR) are primary surgical treatment options for HCC.The aim of the study was to assess mortality within 2 years postdiagnosis among patients with HCC according to their treatment modalities.We examined data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database between 2001 and 2009. SEER registries collect demographics, cancer stage and historical types, and treatments. Medicare claims include diagnoses, procedures, and survival status for each beneficiary. Patients with HCC were identified using the International Classification of Disease Oncology, Third Edition Site code C22.0 and Histology Code 8170-8175. Treatment modalities were LT, SR, or nonsurgical treatment.Total of 11,187 cases was included (age at diagnosis: 72 years, 69% male, 67% White). HCC patients who underwent LT were younger (61 vs 71 years), sicker (presence of decompensated cirrhosis: 80% vs 23%), and less likely to die within 2 years (29% vs 44%, all P < 0.01), compared to SR patients. In multivariate analysis, older age (HR: 1.01 [95% CI = 1.01-1.01]), stage of HCC other than local (HR: 1.81[95%CI = 1.70-1.91]), and being treated with SR (HR: 1.95 [95%CI = 1.55-2.46]) were independent predictors of mortality within 2 years. Furthermore, the presence of decompensated cirrhosis (HR: 1.84 [95%CI = 1.73-1.96]) and alcoholic liver disease (HR: 1.19[95%CI = 1.11-1.28]) increased within 2 years mortality.Mortality within 2 years postdiagnosis of HCC was significantly higher in patients treated with SR than LT.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures


Similar articles
-
Comparison of 10-Year Survival Outcomes for Early Single Hepatocellular Carcinoma following Different Treatments.Biomed Res Int. 2021 Mar 19;2021:6638117. doi: 10.1155/2021/6638117. eCollection 2021. Biomed Res Int. 2021. Retraction in: Biomed Res Int. 2023 Jul 12;2023:9827803. doi: 10.1155/2023/9827803. PMID: 34150908 Free PMC article. Retracted.
-
Survival outcomes of liver transplantation versus liver resection among patients with hepatocellular carcinoma: A SEER-based longitudinal study.J Formos Med Assoc. 2019 Apr;118(4):790-796. doi: 10.1016/j.jfma.2018.09.015. Epub 2018 Oct 25. J Formos Med Assoc. 2019. PMID: 30482570
-
Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma.J Surg Res. 2017 Apr;210:253-260. doi: 10.1016/j.jss.2016.11.042. Epub 2016 Nov 30. J Surg Res. 2017. PMID: 28457336
-
Liver transplantation vs liver resection in patients with HBV-related hepatocellular carcinoma beyond Milan criterion: A meta-analysis.Clin Transplant. 2018 Mar;32(3):e13193. doi: 10.1111/ctr.13193. Epub 2018 Jan 30. Clin Transplant. 2018. PMID: 29315813 Review.
-
Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis.Liver Transpl. 2017 Jun;23(6):836-844. doi: 10.1002/lt.24758. Liver Transpl. 2017. PMID: 28295992 Review.
Cited by
-
A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score.J Gastrointest Surg. 2022 Dec;26(12):2486-2495. doi: 10.1007/s11605-022-05451-5. Epub 2022 Sep 13. J Gastrointest Surg. 2022. PMID: 36100827
-
Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma.J Clin Imaging Sci. 2022 Jul 15;12:38. doi: 10.25259/JCIS_47_2022. eCollection 2022. J Clin Imaging Sci. 2022. PMID: 36128344 Free PMC article.
-
Health-Related Quality of Life and Health Care Resource Utilization in Patients With Chronic Liver Disease and Primary Liver Cancer in the United States: Analysis of Medical Expenditure Panel Survey.J Clin Exp Hepatol. 2022 Mar-Apr;12(2):272-277. doi: 10.1016/j.jceh.2021.12.012. Epub 2021 Dec 29. J Clin Exp Hepatol. 2022. PMID: 35535094 Free PMC article.
-
Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma.Nanotheranostics. 2019 Oct 1;3(4):331-341. doi: 10.7150/ntno.39514. eCollection 2019. Nanotheranostics. 2019. PMID: 31687321 Free PMC article.
-
Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221085376. doi: 10.1177/15330338221085376. Technol Cancer Res Treat. 2022. PMID: 35382635 Free PMC article.
References
-
- WHO. World Cancer Report 2014— Available at: http://www.who.int/mediacentre/factsheets/fs297/en. Accessed 2014.
-
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55. - PubMed
-
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–76. - PubMed
-
- Stewart BW, Wild CPE. World Cancer Report 2014. 2014;Lyon, France: International Agency for Research on Cancer, http://www.ebrary.com.proxy.library.vcu.edu - PubMed
-
- SEER. SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer—2015. Available at: http://seer.cancer.gov/statfacts/html/livibd.html Accessed 2015.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials